Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.

CONTEXT In trials, thiazolidinediones (TZDs) increase fracture risk in women, but the effects of discontinuation are unknown. OBJECTIVE The objective was to investigate the effects of TZD use and discontinuation on fractures in women and men. DESIGN This was a longitudinal observational cohort study using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial bone ancillary study. Duration of TZD use and discontinuation during ACCORD, assessed every 2-4 months at clinic visits, were modeled as time-varying covariates in proportional hazards models for occurrence of first non-spine fracture. PARTICIPANTS We studied a total of 6865 participants in ACCORD BONE. MAIN OUTCOME MEASURES Main outcome measures were centrally adjudicated non-spine fracture. RESULTS Average age was 62.4 (SD, 6.6) years; average duration of diabetes was 11.1 (SD, 7.8) years. Rosiglitazone was used by 74% and pioglitazone by 13% of participants. During a mean follow-up of 4.8 (SD, 1.5) years, 262 men and 287 women experienced at least one non-spine fracture. The fracture rate was higher in women with 1-2 years of TZD use (hazard ratio [HR] = 2.32; 95% confidence interval [CI], 1.49, 3.62) or >2 years of TZD use (HR = 2.01; 95% CI, 1.35, 2.98), compared with no use. The fracture rate was reduced in women who had discontinued TZD use for 1-2 years (HR = 0.57; 95% CI, 0.35, 0.92) or > 2 years (HR = 0.42; 95% CI, 0.24, 0.74) compared with current users. TZD use and discontinuation were not associated with non-spine fractures in men. CONCLUSIONS TZD use was associated with increased non-spine fractures in women, but not men, with type 2 diabetes. When women discontinued TZD use, the fracture effects were attenuated.

[1]  Yun-fa Jiang,et al.  Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. , 2014, Bone.

[2]  I. Reid,et al.  The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. , 2014, European journal of endocrinology.

[3]  Alfonso T. Perez,et al.  Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.

[4]  J. Cauley,et al.  Public health impact of osteoporosis. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[5]  R. Guldberg,et al.  The Effect of Rosiglitazone on Bone Mass and Fragility Is Reversible and Can Be Attenuated With Alendronate , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  R. Eastell,et al.  Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. , 2013, The Journal of clinical endocrinology and metabolism.

[7]  E. Vittinghoff,et al.  Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial , 2012, Diabetes Care.

[8]  L. Hofbauer,et al.  Bone, sweet bone—osteoporotic fractures in diabetes mellitus , 2012, Nature Reviews Endocrinology.

[9]  J. Bilezikian,et al.  A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐naïve type 2 diabetes mellitus patients , 2011, Diabetes, obesity & metabolism.

[10]  Z. Rosenwaks,et al.  Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase , 2011, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[11]  A. C. Yazici,et al.  ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study , 2010, Clinical endocrinology.

[12]  Ian J. Douglas,et al.  The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study , 2009, PLoS medicine.

[13]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[14]  C. Furberg,et al.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.

[15]  J. Dormandy,et al.  Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes , 2009, Drug safety.

[16]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[17]  A. Hermann,et al.  Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.

[18]  H. Jick,et al.  Use of thiazolidinediones and fracture risk. , 2008, Archives of internal medicine.

[19]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[20]  B. Zinman,et al.  Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.

[21]  D. Goff,et al.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.

[22]  I. Reid,et al.  The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.

[23]  P. Vestergaard,et al.  Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis , 2007, Osteoporosis International.

[24]  Charles E. McCulloch,et al.  Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models , 2005 .

[25]  C. Cooper,et al.  Use of Oral Corticosteroids and Risk of Fractures , 2000 .

[26]  E. Simpson,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Estrogen Biosynthesis in Human Breast Adipose Tissue: Possible Implications for Breast Cancer Therapy , 2000 .

[27]  E White,et al.  The effect of misclassification of disease status in follow-up studies: implications for selecting disease classification criteria. , 1986, American journal of epidemiology.